

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 April 2020 (02.04.2020)



(10) International Publication Number
WO 2020/068990 A1

(51) International Patent Classification:

C12N 15/86 (2006.01) C07K 14/015 (2006.01)
C07K 7/06 (2006.01)

(21) International Application Number:

PCT/US2019/052969

(22) International Filing Date:

25 September 2019 (25.09.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/736,904 26 September 2018 (26.09.2018) US
62/832,812 11 April 2019 (11.04.2019) US

(71) Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY [US/US]; 1200 E. California Boulevard, Pasadena, California 91125 (US).


(72) Inventors: GRADINARU, Viviana; c/o California Institute of Technology, 1200 E. California Boulevard, Pasadena, California 91125 (US). FLYTZANIS, Nicholas C.; c/o California Institute of Technology, 1200 E. California Boulevard, Pasadena, California 91125 (US). GOEDEN, Nicholas S.; c/o California Institute of Technology, 1200 E. California Boulevard, Pasadena, California 91125 (US).

(74) Agent: PENNEBAKER, Sara; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR TARGETED GENE THERAPY

FIG. 17C



(57) Abstract: Described herein are compositions and kits comprising recombinant adeno-associated viruses (rAAVs) with tropisms showing increased specificity and efficiency of viral transduction in targeted cell-types, for e.g., the brain, and lung. The rAAV compositions described herein also have tropisms showing decreased specificity and decreased efficiency of viral transduction in an off-target cell type, for e.g., the liver. The rAAV compositions described herein encapsidate a transgene, such as a therapeutic nucleic acid. Upon systemic delivery to a subject, the rAAV is capable of increased specificity and increased transduction of the transgene in a target cell-type, as compared to a parental or reference AAV.

[Continued on next page]

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))